Erythropoietin Drugs Market - Top Companies and Manufacturers

Companies Dominating the Erythropoietin Drugs Landscape

Major key players continuously invest in research and development to improve the effectiveness, safety, and delivery methods of EPO drugs. Partnerships with hospitals, clinics, and distribution networks help key players reach a wider audience. Collaborations with local healthcare providers or joint ventures with local manufacturers enable global companies to leverage regional expertise, boost local production, and improve drug availability.

Here are some key players in the erythropoietin drugs market:

AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Amgen, Inc.
Biocon Limited
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
F. Hoffmann-La Roche Ltd.
Intas Pharmaceuticals Ltd.
Johnson & Johnson
Kyowa Kirin Co., Ltd.
LG Chem, Ltd.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Genexine

Browse Key Market Insights with Data Illustration:

Erythropoietin Drugs Market Size & Share, Growth Trends 2037

In the News

In October 2023, Sun Pharma and Zydus Lifesciences Limited signed a licensing deal to co-market Desidustat, a novel medication in India. Desidustat is India's first oral therapy for chronic kidney disease-related anemia.
In October 2023, Genexine and KGbio got the first market approval for innovative long-acting Erythropoietin, Efepoetin alfa, from the Indonesian Food and Drug Authority (BPOM).

Frequently Asked Questions (FAQ)

The erythropoietin drugs sector registered a profitable valuation of USD 10.90 billion in 2024 and is projected to expand at a CAGR of 4.8% during the forecast period, i.e., 2025-2037.

The global erythropoietin drugs sector was valued at USD 10.90 billion in 2024 and is projected to register USD 20.04 billion in 2037, expanding at a profitable CAGR of 4.8% during the forecast period, i.e., 2025-2037.

The major players in the market are Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Kyowa Kirin Co., Ltd, and others.

By product type, the biosimilars segment is estimated to reach USD 8.8 billion by 2037. EPO drugs, which are used primarily to treat anemia associated with CKD, cancer chemotherapy, and other chronic illnesses, have long been dominated by branded biologic products.

North America EPO drugs market is poised to register the largest share of 26.6% by 2037. The market in the region is largely driven by high prevalence rates of chronic CKD and cancer, which often result in anemia.

Erythropoietin Drugs Market - Top Companies and Manufacturers

Companies Dominating the Erythropoietin Drugs Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the erythropoietin drugs market?

What is the outlook for the erythropoietin drugs market?

Who are the major players dominating the erythropoietin drugs market?

Which product type segment will capture the significant market share for the erythropoietin drugs sector by 2037?

Which region will provide more business opportunities for the growth of the erythropoietin drugs market in the future?